Charity makes three research awards

Article

One of the world's leading eye research centres, the UCL Institute of Ophthalmology, has been awarded three PhD studentships worth £280,000 tenable from October 2009.

One of the world's leading eye research centres, the UCL Institute of Ophthalmology, has been awarded three PhD studentships worth £280,000 tenable from October 2009. They were awarded from Fight for Sight, a UK leading charity dedicated to funding research into the prevention and treatment of blindness and eye disease.

The awards will enable researchers to develop new treatments for patients with conditions affecting the retina and the cornea.

The studentships will be allocated for supervision under the following members of staff at the UCL Institute of Ophthalmology:

Professor Robin Ali and Mr Frank Larkin will supervise an award for research into a viral gene therapy that could enhance the quality of donor corneas stored in eye banks, leading to less wastage, and improved functionality and longevity for transplanted corneas.

Professor Mike Cheetham will oversee the award for research into key molecular components that help in the manufacture of rhodopsin (a transmembrane protein) within the cell and the protection against the formation of its faulty form. Once identified, these components will be targets for new therapies to treat rhodopsin retinitis pigmentosa, one of the most common causes of inherited blindness.

Finally, Professor Shin-ichi Ohnuma and Dr Yamamoto Yoshiyuki will preside over the award for a study into genetically determined diseases of the cornea that may lead to blindness. This research will explore options for therapies to treat these diseases.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.